An allogeneic CAR-T cell therapy designed to target cancer cells that express the cell surface-associated C-terminal antigen Mucin-1 (P-MUC1C-ALLO1) will be tested for safety, tolerability, and response to treatment in patients with solid cancers, including RCC (NCT05239143). The gene discussed is MUC1; the disease is renal cell carcinoma.